



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/20		A2	(11) International Publication Number: WO 97/04750
			(43) International Publication Date: 13 February 1997 (13.02.97)
(21) International Application Number: PCT/EP96/03326		sex CM19 5AW (GB). CLARK, Michael, Sidney, George [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AG (GB). LOUDON, Julia, Mary [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).	
(22) International Filing Date: 29 July 1996 (29.07.96)			
(30) Priority Data:			
9515624.6 29 July 1995 (29.07.95) GB 9606684.0 29 March 1996 (29.03.96) GB			
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): NAPPER, James, Albert [GB/GB]; SmithKline Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). MORTIMER, Neil [GB/GB]; SmithKline Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). O'BRIEN, Karen, Triona [IE/GB]; SmithKline Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). MANEK, Sultan, James [GB/GB]; SmithKline Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). KUMAR, Rajinder [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Es-			
(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).			
Published <i>Without international search report and to be republished upon receipt of that report.</i>			
(54) Title: PROCESS FOR PREPARING SOLID DOSAGE FORMS OF VERY LOW-DOSE DRUGS			
(57) Abstract			
<p>A drug formulation process which comprises admixing carrier particles with a solution of drug in water in a quantity of 1-3 % by weight of solution to total mix and a method of treatment and/or prophylaxis of dementia, which method comprises administering to the patient [R-(Z)]-α-(methoxyimino)-α-(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride at a daily dose below 0.01 mg/kg and pharmaceutical compositions used therein.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

PROCESS FOR PREPARING SOLID DOSAGE FORMS OF VERY LOW-DOSE DRUGS

This invention relates to a method of formulating solid dosage forms of drugs and to solid dosage forms produced thereby, in particular solid dosage forms containing low dose of drug. The invention also relates to a method of treatment and/or prophylaxis of dementia and unit dosage forms useful therein.

The usual challenge in manufacturing solid dosage forms of very low-dose drugs, for example with active doses around 5-125 microgramme (μg) (for example 0.004-0.1% by weight of drug to total solid), is to ensure homogeneity. The technical problem is how to distribute the drug substance evenly among the large amount of excipient particles.

The simplest way of manufacturing tablets is simply to blend all the ingredients as dry powders and tablet them ("direct compression"). This is rarely successful for low-dose drugs; a common problem being segregation of the powder blend during tableting. A variation of this method which has been successful for low-dose drugs is known as "trituration", and is sometimes referred to as "ordered mixing" or "interactive mixing". Very fine particles of the drug are first mixed with a small portion of excipient; the product then mixed with a slightly larger portion of excipient and so on until the desired mix is obtained. This method relies on the fine drug particles adhering electrostatically to the larger excipient ones, thus preventing segregation. The method works with some drugs, but success depends on the surface properties of both drug and excipient, and the method is very laborious. EP0503521 describes the application of this method to steroidal drugs with high binding affinity and low demixing potential for certain excipients.

A preferred alternative method for formulating low dose drugs is known as "wet granulation". The drug is dissolved in water or another solvent, and blended with excipients including a binder, for example povidone, to form a wet mass containing 5-20% by weight of solution to total weight of granulation mix, which is then dried off in a separate step. The binder causes particles of excipient to clump together, and as the mass dries these clumps ("granules") either contain or are coated with the drug. This is effective but cumbersome since the drying step requires special equipment, and generally involves high temperatures which may degrade labile drugs. Also, the use of the binder requires the further inclusion of a disintegrant such as sodium starch glycolate or starch to help the tablet, which is cohesive, to disperse in the stomach.

Fluid bed granulation has been used to achieve content uniformity of low dose ($1\mu\text{g}$ -10mg) tablets (Thiel et al., J. Pharm. Pharmacol. 1986, 38, 335-343). In this process, the micronised drug is blended as a powder with other excipients, then loaded into a fluid bed granulator, and the powders are agglomerated by spraying on a solution of a binder; drying takes place concomitantly. The process does not require a separate drying

step, but it does require the use of micronised drug, and also incorporates a separate blending step prior to granulation. It also requires specialised equipment and precise optimisation of the process parameters.

5 Another process for formulating low dose drugs is known as carrier granulation (Michoel et al., Pharmaceutical Technology June 1988, 66-84). This functions by spraying a solution of binder such as povidone in water onto relatively large excipient particles such as hydrous lactose and then spraying small dry drug substance particles onto that, thus coating the excipient with drug particles which are stuck on by the binder. The quantity of solution used was 3.3-3.5% by weight of solution to total granulation mix. The method
10 was applied to a formulation containing 4-5% drug by weight. This method also requires drying; the drug particle size needs to be very small, which often requires an extra milling step and the very fine drug powder may not flow at all well; and the formula still requires a disintegrant.

Dahl et al., Drug Development and Industrial Pharmacy 1990, 16 (12), 1881-1891,
15 describes the preparation of solid capsule formulations using a spray-on liquid drug carrier. The model drug is dissolved in a non-volatile solvent, propylene carbonate, and sprayed onto a compressible sugar at a loading of around 0.01% by weight of drug to total solid, to give a final unit dose of 35µg. The solvent, being non-volatile, remains in the blend. It is added at around 5% by weight of the total formulation; lower ratios of solvent to solid
20 resulted in decreased ability to disintegrate and dissolve. The resulting, somewhat sticky, powder showed some difficulties in automated encapsulation machines, and would be likely to give significant problems in tableting.

Yalkowski (US4,489,026) describes a process which involves very slowly spraying a dilute solution of drug in a volatile inert solvent, preferably an organic solvent having a
25 boiling point lower than 80°C, onto excipient powder in an open coating pan; a continuous flow of air dries the product during the spraying process. This process was applied to drugs with a unit dose of 10ug or less. The spray rate is limited to 1-10ml/min, making the process suitable only for very small batch-sizes (the example quoted prepared 1000 tablets). The weight ratio of solution to carrier used was 15%; also, the use of volatile
30 organic liquids is now regarded as a significant hazard, requiring solvent-recovery processes and explosion-proof equipment.

Katdare (US4,898,736) describes a simplified version of this process, suitable for unit doses of 50-1000µg; the drug, dissolved in an easily evaporated solvent such as ethanol, methanol, acetone or tetrahydrofuran, is simply blended with excipients in a ratio
35 of 2.26% or 6.75% and then dried, followed by lubrication and tableting. This process is in principle suitable for commercial scale manufacture, but does still have the problems associated with the use of volatile organic solvents.

According to the present invention there is provided a drug formulation process which comprises admixing carrier particles with a solution of drug in water in a quantity of 1-3% by weight of solution to total mix.

5 The resulting mixture may be formulated into suitable unit dose presentation, for example by tableting and optionally film coating the tablets or by encapsulation.

It may be convenient to make the initial drug/carrier mix with a higher drug concentration, and then in a separate step blending that with further carrier, and this may be particularly useful where a range of tablet strengths is required. The separate blending step aids drying by the dilution effect, that is, the residual water is distributed through a greater quantity of carrier powder, and by the longer mixing time. The dilution is
10 conveniently in the range 4/1 to 40/1 carrier/concentrate by weight, depending upon the processing characteristics of the carrier. A convenient dilution ratio for lactose monohydrate is 10/1.

Where the dilution step is not employed, the solution/mix weight ratio is more
15 preferably up to 2% by weight.

The optimum quantity of solution will depend upon the absorbent qualities of the carrier particles, the solubility of the drug and the characteristics of the mixing device, the quantity of solution being chosen so as to allow even distribution of drug while avoiding the need for a heated drying step.

20 The mixing step is preferably carried out in a high shear mixer.

The carrier may be any suitable soluble, directly compressible pharmaceutically acceptable excipient such as anhydrous lactose, lactose monohydrate, mannitol, or an insoluble, directly compressible pharmaceutically acceptable excipient such as microcrystalline cellulose or dicalcium phosphate, preferably a soluble excipient.

25 Any drug having a sufficient degree of solubility in water may be formulated by the process of the invention. The concentration of drug in the solution is dependent on the unit dose of drug required, the upper limit being dependent on the solubility of the drug.

30 During mixing, the carrier particles are evenly coated with a very thin film of drug solution. Some of the water naturally dries off during the mixing since there is normally a small airflow through the mixer; the remaining amount is so low that drying is not specifically required. If the tablets are film-coated, a degree of further drying may be obtained during the coating process.

The process of the invention has a number of advantages:

- it does not require any milling of the drug substance
- 35 - there is no need for a drying step. This simplifies processing and reduces production costs; heat labile drugs do not suffer at the temperature required for drying; for drugs

which are highly potent, the omission of the drying step makes it easier to contain dust, improving safety for the factory worker

- the use of volatile organic solvents is avoided

- there is no need to add a binder

5 - there is no need to add a disintegrant when the excipient is a highly soluble one.

Optional additives in the final mix include a disintegrant; a range of acidic or alkaline excipients to improve chemical stability of the drug in the formulation such as sodium dihydrogen citrate, preferably included in the initial mix; a lubricant such as magnesium stearate; and a glidant such as colloidal silica.

10 The present invention further provides a pharmaceutical composition comprising a drug formulated in accordance with the process of the invention and the use of said composition as an active therapeutic substance.

The invention additionally provides a pharmaceutical composition comprising a drug, obtainable by the process of the invention and the use of said composition as an
15 active therapeutic substance.

The process of the invention is particularly useful for formulating [R-(Z)]- α -(methoxyimino)- α -(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride (compound X) with active doses around 5-125 microgramme (μ g). Compound X and methods for its preparation are disclosed in EP-A-0392803, WO95/31456 and
20 WO93/17018. The compound enhances acetylcholine function via an action at muscarinic receptors within the central nervous system, and is therefore of potential use in the treatment and/or prophylaxis of dementia in mammals.

In particular the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and compound X at a level of up to 0.1% by weight
25 of drug to carrier, 0% volatile organic solvent and 0% binder.

EP-A-0392803 suggests the suitable daily dose for compound X and other compounds disclosed therein as 0.01-5mg/kg. It has been surprisingly found through administration to human patients that efficacy as a cognition enhancer may be obtained at daily doses below 0.01mg/kg more particularly 0.003mg/kg and below, for example
30 0.0001-0.003mg/kg, such as 0.00035-0.003mg/kg, 0.0007-0.003mg/kg, 0.0001-0.0007mg/kg or 0.00035-0.002mg/kg.

Accordingly the present invention provides a method of treatment and/or prophylaxis of dementia, and more particularly a method of enhancing cognition in a patient, which method comprises administering to the patient compound X at a daily dose
35 below 0.01mg/kg, more preferably 0.003mg/kg or less. The invention also relates to the use of compound X in the manufacture of a medicament for the treatment and/or prophylaxis of dementia at a daily dose below 0.01mg/kg, more preferably of

0.003mg/kg or less. The invention further relates to a pharmaceutical composition for the treatment and/or prophylaxis of dementia which comprises compound X at a unit dose suitable for administration at a daily dose below 0.01mg/kg, more preferably of 0.003mg/kg or less, and a pharmaceutically acceptable carrier.

5 Suitable unit doses to achieve such daily doses are 5, 12.5, 25, 50 or 75µg, administered twice daily and, in the case of 50µg, once daily. Such unit doses are calculated on the basis of 50-70kg individuals. The invention extends to the method, use or composition defined above wherein compound X is provided in such unit doses.

10 The invention further provides a pharmaceutical composition comprising compound X of the invention and/or formulated in accordance with the process of the invention, in unit dose form selected from the range 5-125µg per unit dose, such as 5, 12.5, 25, 50 or 75µg per unit dose and the use of said composition as an active therapeutic substance, in particular in the treatment and/or prophylaxis of dementia.

15 **EXAMPLE**

Formulation of compound X

To make 100kg of blend for tableting or encapsulation, at 100ug drug per 150mg excipient:

- 20 - dissolve 67g drug in 1liter of water (i.e. 1% of water (1.067% of solution) on a weight basis)
- slowly add this to 100kg of a "direct compression" grade of lactose monohydrate in a high-shear mixer-granulator
- blend with 0.25kg lubricant (Magnesium Stearate) and 0.15kg Glidant (Colloidal
- 25 Silica)
- tablet
- filmcoat (optional)

- 30 To make 100kg of blend for tableting or encapsulation, at 100ug drug per 150mg excipient, by way of a concentrate:
- dissolve 67g drug in 0.1 liter of water
- slowly add this to 9.8kg of a "direct compression" grade of lactose monohydrate and 0.2kg of acidifying agent (Sodium Dihydrogen Citrate) in a high-shear mixer-granulator, followed by a further 0.1 liter of water to rinse the containers used, while
- 35 mixing vigorously with a chopper speed of around 1500rpm and then raising the speed to around 3000rpm, for 10-20 minutes total mixing time (i.e. a total of 2% of water (2.67% of solution) is added on a weight basis relative to the amount of concentrate)

- sieve the resulting concentrate into a tumble-blender
 - blend with 88kg further lactose and 1.8kg Sodium Dihydrogen Citrate, then blend in 0.15kg Glidant (Colloidal Silica) and 0.25kg lubricant (Magnesium Stearate)
 - tablet
- 5 - filmcoat (optional)

To make unit doses of 75, 50, 25, 12.5 and 5µg in 150mg excipient, the amount of drug used in the above methods is 50, 33.6, 16.8, 8.4 and 3.3g respectively.

CLAIMS

1. A drug formulation process which comprises admixing carrier particles with a solution of drug in water in a quantity of 1-3% by weight of solution to total mix.
- 5 2. A process according to claim 1 wherein the carrier is a soluble or an insoluble directly compressible pharmaceutically acceptable excipient.
3. A process according to claim 2 wherein the carrier is a soluble excipient selected from anhydrous lactose, lactose monohydrate and mannitol.
4. A process according to claim 3 wherein the mixture further comprises an acidic or alkaline excipient to improve chemical stability of the drug in the formulation.
- 10 5. A process according to any preceding claim which further comprises blending the mixture with further carrier and/or one or more additives selected from a disintegrant; an acidic or alkaline excipient to improve chemical stability of the drug in the formulation, a lubricant and a glidant
- 15 6. A process according to claim 5 wherein the mix is blended with further carrier in a weight ratio of 1/4 to 1/40.
7. A process according to any preceding claim wherein the mixture is formulated into a unit dose presentation.
8. A process according to any preceding claim for formulating [R-(Z)]- α -(methoxyimino)- α -(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride.
- 20 9. A pharmaceutical composition comprising a drug, obtainable by the process of any preceding claim.
10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and [R-(Z)]- α -(methoxyimino)- α -(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile
- 25 monohydrochloride at a level of up to 0.1% by weight of drug to carrier, 0% volatile organic solvent and 0% binder.
11. A composition according to claim 10 wherein the carrier is a soluble or an insoluble directly compressible pharmaceutically acceptable excipient.
12. A composition according to claim 11 wherein the carrier is a soluble excipient
- 30 selected from anhydrous lactose, lactose monohydrate and mannitol.
13. A composition according to any of claims 10 to 12 which also comprises one or more additives selected from a disintegrant; an acidic excipient to improve chemical stability of the drug in the formulation, a lubricant and a glidant
14. A composition according to claim 13 which comprises lactose monohydrate,
- 35 sodium dihydrogen citrate, colloidal silica and magnesium stearate.
15. A composition according to any of claims 10 to 14 formulated into a unit dose presentation.

16. A method of treatment and/or prophylaxis of dementia, which method comprises administering to the patient [R-(Z)]- α -(methoxyimino)- α -(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride at a daily dose below 0.01mg/kg.
17. The use of [R-(Z)]- α -(methoxyimino)- α -(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride in the manufacture of a medicament for the treatment and/or prophylaxis of dementia at a daily dose below 0.01mg/kg.
18. A pharmaceutical composition for the treatment and/or prophylaxis of dementia which comprises [R-(Z)]- α -(methoxyimino)- α -(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride at a unit dose suitable for administration at a daily dose below 0.01mg/kg, and a pharmaceutically acceptable carrier.
19. A method, use or composition according to claim 16, 17 or 18 wherein the daily dose is 0.003mg/kg or less.
20. A method, use or composition according to claim 19 wherein the daily dose is 0.0001-0.003mg/kg.
21. A method, use or composition according to claim 20 wherein the daily dose is 0.00035-0.003mg/kg.
22. A method, use or composition according to claim 20 wherein the daily dose is 0.0007-0.003mg/kg.
23. A method, use or composition according to claim 20 wherein the daily dose is 0.0001-0.0007mg/kg.
24. A method, use or composition according to claim 20 wherein the daily dose is 0.00035-0.002mg/kg.
25. A method, use or composition according to claim 16, 17 or 18 wherein the compound is presented in a unit dose of 5, 12.5, 25, 50 or 75 μ g, administered twice daily or, in the case of 50 μ g, once daily.
26. A pharmaceutical composition according to claim 9 as dependent on claim 8 or according to any of claims 10 to 15, in unit dose form selected from the range 5-125 μ g per unit dose.
27. A pharmaceutical composition according to claim 26 comprising 5, 12.5, 25, 50 or 75 μ g per unit dose
28. A pharmaceutical composition according to claim 9, according to any of claims 10 to 15 or according to claim 26 or 27 for use as an active therapeutic substance.
29. A pharmaceutical composition according to claim 9 as dependent on claim 8, according to any of claims 10 to 15 or according to claim 26 or 27 for use in the treatment and/or prophylaxis of dementia.
30. A method of treatment and/or prophylaxis of dementia, which method comprises administering to the patient an effective amount of a composition according to claim 29.

31. Use of a pharmaceutical composition according to claim 29 in the manufacture of a medicament for the treatment and/or prophylaxis of dementia.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/14, 9/20		A3	(11) International Publication Number: WO 97/04750
			(43) International Publication Date: 13 February 1997 (13.02.97)
(21) International Application Number: PCT/EP96/03326 (22) International Filing Date: 29 July 1996 (29.07.96) (30) Priority Data: 9515624.6 29 July 1995 (29.07.95) GB 9606684.0 29 March 1996 (29.03.96) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): NAPPER, James, Albert [GB/GB]; SmithKline Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). MORTIMER, Neil [GB/GB]; SmithKline Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). O'BRIEN, Karen, Triona [IE/GB]; SmithKline Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). MANEK, Sultan, James [GB/GB]; SmithKline Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). KUMAR, Rajinder [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Es-		sex CM19 5AW (GB). CLARK, Michael, Sidney, George [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AG (GB). LOUDON, Julia, Mary [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). (74) Agent: VALENTINE, Jill, Barbara; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB). (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 27 March 1997 (27.03.97)	
(54) Title: PROCESS FOR PREPARING SOLID DOSAGE FORMS OF VERY LOW-DOSE DRUGS			
(57) Abstract			
A drug formulation process which comprises admixing carrier particles with a solution of drug in water in a quantity of 1-3 % by weight of solution to total mix and a method of treatment and/or prophylaxis of dementia, which method comprises administering to the patient [R-(Z)]- α -(methoxyimino)- α -(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride at a daily dose below 0.01 mg/kg and pharmaceutical compositions used therein.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International Application No

PC 1/EP 96/03326

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/14 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 17168 A (APPLIED ANALYTICAL INDUSTRIES) 29 June 1995 see the whole document ---	1-7,9
A	US 4 489 026 A (S. H. YALKOWSKY) 18 December 1984 cited in the application see the whole document ---	1-7,9
A	US 4 898 736 A (A. V. KATDARE) 6 February 1990 cited in the application see the whole document ---	1-7,9
-/-		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 February 1997

Date of mailing of the international search report

1 1. 02. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

International Application No

PLI/EP 96/03326

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 101, no. 8, 20 August 1984 Columbus, Ohio, US; abstract no. 60165, XP002024576 see abstract & JP 59 070 614 A (ASAHI) 21 April 1984 ---	1-7,9
A	EP 0 392 803 A (BEECHAM GROUP) 17 October 1990 cited in the application see the whole document -----	8,10-31

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 96/03326

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 16-25 AND 30
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/03326

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9517168	29-06-95	ZA-A- 9309565	11-08-94
		AU-A- 1515595	10-07-95
		CA-A- 2176461	29-06-95
		EP-A- 0735864	09-10-96

US-A-4489026	18-12-84	NONE	

US-A-4898736	06-02-90	NONE	

EP-A-392803	17-10-90	AU-B- 619969	06-02-92
		AU-A- 5315990	18-10-90
		CA-A- 2014379	13-10-90
		JP-A- 3007285	14-01-91
		PT-B- 93753	30-08-96
		US-A- 5278170	11-01-94
